Sign in or Register   Sign in or Register
  |  

Mouse Anti-PALB2 Recombinant Antibody (1E7) (CBMAB-P0709-YC)

Provided herein is a Mouse monoclonal antibody against Human Partner And Localizer Of BRCA2. The antibody can be used for immunoassay techniques, such as WB.
See all PALB2 antibodies

Summary

Host Animal
Mouse
Specificity
Human
Clone
1E7
Antibody Isotype
IgG1
Application
WB

Basic Information

Specificity
Human
Antibody Isotype
IgG1
Clonality
Monoclonal
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
PBS, pH 7.3, containing 1% BSA, 50% glycerol and 0.02% sodium azide
Storage
Store at 4°C short term (1-2 weeks). Aliquot and store at-20°C long term. Avoid repeated freeze/thaw cycles.

Target

Full Name
Partner And Localizer Of BRCA2
Introduction
PALB2 is a protein that may function in tumor suppression. This protein binds to and colocalizes with the breast cancer 2 early onset protein (BRCA2) in nuclear foci and likely permits the stable intranuclear localization and accumulation of BRCA2.
Entrez Gene ID
79728
UniProt ID
Q86YC2
Alternative Names
Partner And Localizer Of BRCA2; FANCN; Fanconi Anemia, Complementation Group N; Mutant Partner And Localizer Of BRCA2; PNCA3;
Function
Plays a critical role in homologous recombination repair (HRR) through its ability to recruit BRCA2 and RAD51 to DNA breaks (PubMed:16793542, PubMed:19423707, PubMed:19369211, PubMed:22941656, PubMed:24141787, PubMed:28319063).
Strongly stimulates the DNA strand-invasion activity of RAD51, stabilizes the nucleoprotein filament against a disruptive BRC3-BRC4 polypeptide and helps RAD51 to overcome the suppressive effect of replication protein A (RPA) (PubMed:20871615).
Functionally cooperates with RAD51AP1 in promoting of D-loop formation by RAD51 (PubMed:20871616).
Serves as the molecular scaffold in the formation of the BRCA1-PALB2-BRCA2 complex which is essential for homologous recombination (PubMed:19369211).
Via its WD repeats is proposed to scaffold a HR complex containing RAD51C and BRCA2 which is thought to play a role in HR-mediated DNA repair (PubMed:24141787).
Essential partner of BRCA2 that promotes the localization and stability of BRCA2 (PubMed:16793542).
Also enables its recombinational repair and checkpoint functions of BRCA2 (PubMed:16793542).
May act by promoting stable association of BRCA2 with nuclear structures, allowing BRCA2 to escape the effects of proteasome-mediated degradation (PubMed:16793542).
Binds DNA with high affinity for D loop, which comprises single-stranded, double-stranded and branched DNA structures (PubMed:20871616).
May play a role in the extension step after strand invasion at replication-dependent DNA double-strand breaks; together with BRCA2 is involved in both POLH localization at collapsed replication forks and DNA polymerization activity (PubMed:24485656).
Biological Process
Animal organ morphogenesisIEA:Ensembl
Double-strand break repair via homologous recombinationManual Assertion Based On ExperimentIDA:UniProtKB
Embryonic organ developmentIEA:Ensembl
Inner cell mass cell proliferationIEA:Ensembl
Mesoderm developmentIEA:Ensembl
Multicellular organism growthIEA:Ensembl
Negative regulation of apoptotic processIEA:Ensembl
Post-anal tail morphogenesisIEA:Ensembl
SomitogenesisIEA:Ensembl
Cellular Location
Nucleus
Colocalizes with BRCA2 and BRCA1 in nuclear foci.
Involvement in disease
Breast cancer (BC):
A common malignancy originating from breast epithelial tissue. Breast neoplasms can be distinguished by their histologic pattern. Invasive ductal carcinoma is by far the most common type. Breast cancer is etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. Mutations at more than one locus can be involved in different families or even in the same case.
Fanconi anemia complementation group N (FANCN):
A disorder affecting all bone marrow elements and resulting in anemia, leukopenia and thrombopenia. It is associated with cardiac, renal and limb malformations, dermal pigmentary changes, and a predisposition to the development of malignancies. At the cellular level it is associated with hypersensitivity to DNA-damaging agents, chromosomal instability (increased chromosome breakage) and defective DNA repair.
Pancreatic cancer 3 (PNCA3):
A malignant neoplasm of the pancreas. Tumors can arise from both the exocrine and endocrine portions of the pancreas, but 95% of them develop from the exocrine portion, including the ductal epithelium, acinar cells, connective tissue, and lymphatic tissue.

Preobrazhenskaya, E. V., Shleykina, A. U., Gorustovich, O. A., Martianov, A. S., Bizin, I. V., Anisimova, E. I., ... & Imyanitov, E. N. (2021). Frequency and molecular characteristics of PALB2‐associated cancers in Russian patients. International Journal of Cancer, 148(1), 203-210.

Nepomuceno, T. C., Carvalho, M. A., Rodrigue, A., Simard, J., Masson, J. Y., & Monteiro, A. N. (2021). PALB2 variants: protein domains and cancer susceptibility. Trends in cancer, 7(3), 188-197.

Wokołorczyk, D., Kluźniak, W., Stempa, K., Rusak, B., Huzarski, T., Gronwald, J., ... & Cybulski, C. (2021). PALB2 mutations and prostate cancer risk and survival. British Journal of Cancer, 125(4), 569-575.

Wu, S., Zhou, J., Zhang, K., Chen, H., Luo, M., Lu, Y., ... & Chen, Y. (2020). Molecular mechanisms of PALB2 function and its role in breast cancer management. Frontiers in Oncology, 10, 301.

Yang, X., Leslie, G., Doroszuk, A., Schneider, S., Allen, J., Decker, B., ... & Tischkowitz, M. (2020). Cancer risks associated with germline PALB2 pathogenic variants: an international study of 524 families. Journal of clinical oncology, 38(7), 674.

Hu, Z. Y., Liu, L., Xie, N., Lu, J., Liu, Z., Tang, Y., ... & Ouyang, Q. (2020). Germline PALB2 mutations in cancers and its distinction from somatic PALB2 mutations in breast cancers. Frontiers in Genetics, 11, 829.

Zhou, J., Wang, H., Fu, F., Li, Z., Feng, Q., Wu, W., ... & Chen, Y. (2020). Spectrum of PALB2 germline mutations and characteristics of PALB2‐related breast cancer: Screening of 16,501 unselected patients with breast cancer and 5890 controls by next‐generation sequencing. Cancer, 126(14), 3202-3208.

Ducy, M., Sesma-Sanz, L., Guitton-Sert, L., Lashgari, A., Gao, Y., Brahiti, N., ... & Masson, J. Y. (2019). The tumor suppressor PALB2: inside out. Trends in biochemical sciences, 44(3), 226-240.

Simhadri, S., Vincelli, G., Huo, Y., Misenko, S., Foo, T. K., Ahlskog, J., ... & Xia, B. (2019). PALB2 connects BRCA1 and BRCA2 in the G2/M checkpoint response. Oncogene, 38(10), 1585-1596.

Boonen, R. A., Rodrigue, A., Stoepker, C., Wiegant, W. W., Vroling, B., Sharma, M., ... & van Attikum, H. (2019). Functional analysis of genetic variants in the high-risk breast cancer susceptibility gene PALB2. Nature communications, 10(1), 5296.

Ask a question We look forward to hearing from you.
0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Loading...
Have you used Mouse Anti-PALB2 Recombinant Antibody (1E7)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Documents

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Go to
Compare